MHRA Requests Feedback Ahead of Brexit
The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) is conducting a survey to better understand how it can support its customers in the run up to the country’s exit from European Union.
MHRA is embarking on a major operational transformation scheme across its three expert centers: the MHRA regulatory center, the National Institute for Biological Standards and Control, and the Clinical Practice Research Datalink. This includes significant investment in the organization’s digital capabilities and infrastructure, it noted.
The survey should take about 10-15 minutes to complete, depending on how many different parts of the agency an individual deals with. All responses will be held in strict confidence and will not be passed on to the agency in a way that would allow any individual contribution to be identified, according to the survey organizers.
According to the MHRA, “understanding your needs and priorities is essential to inform our plans and will help us to strategically shape our services, investment decisions, and underlying operational processes and systems. The work we do now will underpin how we are able to meet your needs for years to come.”
The survey was designed in collaboration with PA Consulting, a consulting, technology, and innovation firm, and Woodnewton Associates, an independent strategic research agency. It closes on Wednesday September 27. To complete it, click here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
